SCHEMBL3476602

SCHEMBL3476602

COC(=O)CCCC(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 5/20 0.83
HDAC3 O15379 5/20 0.83
HDAC4 P56524 5/20 0.83
HDAC1 Q13547 5/20 0.83
HDAC7 Q8WUI4 5/20 0.83
HDAC2 Q92769 5/20 0.83
HDAC10 Q969S8 5/20 0.83
HDAC11 Q96DB2 5/20 0.83
HDAC8 Q9BY41 5/20 0.83
HDAC6 Q9UBN7 5/20 0.83
HDAC9 Q9UKV0 5/20 0.83
HDAC5 Q9UQL6 5/20 0.83
CDK6 Q00534 3/20 0.83
CDK2 P24941 14/20 0.75
CCNE2 O96020 13/20 0.75
CCNE1 P24864 13/20 0.75
CDK4 P11802 7/20 0.69
CCND1 P24385 7/20 0.69
CCNB2 O95067 6/20 0.69
CDK1 P06493 6/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3477501 0.98 HDAC3 (0.83) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3467498 0.97 HDAC3 (0.84) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3467490 0.94 CDK2 (0.78) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL4203348 0.91 HDAC3 (1.00) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3466814 0.90 CCND3 (0.86) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL4207837 0.90 CCND3 (0.83) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3467568 0.90 CDK2 (0.74) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL18231939 0.89 CCND3 (0.85) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL4211024 0.89 HDAC3 (1.00) CCND3HDAC3HDAC4HDAC1HDAC7
SCHEMBL9950338 0.89 HDAC3 (0.82) CCND3HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563741-B2 CDK inhibitors containing a zinc binding moiety CURIS, INC. (US) 2013-10-22 US disclosed
US-20120165335-A1 CDK INHIBITORS CURIS, INC. 2012-06-28 US disclosed
WO-2010075542-A1 CDK INHIBITORS CURIS, INC. (US) 2010-07-01 WO disclosed
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-04-09 US disclosed
WO-2009036016-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CDK3, CDKL1, CDKL3 CCND3 85/4885HDAC3 36/4885HDAC4 22/4885
US-20120165335-A1 CDK INHIBITORS CDK3, CDK6, CDKL1 CCND3 47/4885HDAC3 560/4885HDAC4 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.